Fibroblast activity is central to normal wound healing and pathological fibrosis. Fibroblasts synthesize extracellular-matrix proteins, respond to mechanical and inflammatory signals, communicate with immune and vascular cells, and help restore tissue integrity after injury. MSCs and MSC-derived extracellular vesicles can alter fibroblast proliferation, migration, cytokine production, matrix synthesis, and matrix degradation in experimental systems. These effects are not uniformly antifibrotic: the direction of response depends on tissue, injury stage, cell or EV product, dose, and local signaling. A reduction in fibroblast proliferation alone does not establish beneficial remodeling because adequate fibroblast function is required for normal repair.
Figure 1 placeholder — Fibroblast activity
Myofibroblast differentiation
Myofibroblast differentiation is the transition of fibroblasts or other precursor populations toward a contractile, matrix-producing phenotype characterized in part by alpha-smooth-muscle actin and increased extracellular-matrix synthesis. Transforming growth factor-beta is a major driver, interacting with mechanical tension, integrins, inflammatory mediators, and other pathways. Myofibroblasts are useful during wound closure but persistent activation can promote fibrosis and tissue stiffness. MSC- or EV-associated signals may modify this transition in preclinical models. Interpretation requires functional and tissue-level evidence rather than reliance on a single marker such as alpha-smooth-muscle actin.
Figure 2 placeholder — Myofibroblast differentiation
Collagen deposition
Collagen deposition is necessary for structural repair, but excessive or disorganized collagen accumulation can impair tissue architecture and function. Fibrosis involves not only the quantity of collagen but also collagen type, cross-linking, alignment, turnover, and spatial distribution. MSCs and EVs may influence collagen synthesis indirectly through inflammatory signaling, fibroblast behavior, transforming growth factor-beta pathways, oxidative stress, and matrix-remodeling enzymes. Lower collagen content is not automatically beneficial: inadequate matrix formation can weaken healing tissue. The clinically relevant goal is appropriate matrix restoration rather than indiscriminate suppression of collagen.
Figure 3 placeholder — Collagen deposition
Matrix metalloproteinases
Matrix metalloproteinases are zinc-dependent proteolytic enzymes that degrade extracellular-matrix components and regulate signaling molecules. Their activity is balanced by tissue inhibitors of metalloproteinases. MSCs, EVs, fibroblasts, macrophages, and other cells can influence this protease-inhibitor network. Increased matrix metalloproteinase activity can facilitate removal of excessive scar matrix, but uncontrolled proteolysis can damage normal matrix, destabilize tissue, or alter inflammation. Measuring expression of one metalloproteinase without assessing activity, inhibitors, substrates, and tissue consequences provides an incomplete picture of remodeling.
Figure 4 placeholder — Matrix metalloproteinases
Scar remodeling
Scar remodeling is the later reorganization of repair tissue after the initial wound response. Collagen fibers can be degraded, replaced, cross-linked, and realigned while cellularity and vascularity change and tissue mechanics evolve. Beneficial remodeling can improve tensile properties and reduce excessive scar burden, but complete restoration of native architecture is uncommon after major injury. MSC- or EV-related changes in scar thickness, collagen organization, matrix turnover, or mechanical properties are mechanistic findings. They should not be labeled regeneration unless the tissue's original structure and function are demonstrably restored.
Figure 5 placeholder — Scar remodeling
Organ-specific fibrosis
Organ-specific fibrosis reflects the fact that fibrotic disease differs substantially among lung, liver, kidney, heart, skin, musculoskeletal tissues, and other organs. Resident fibroblast populations, epithelial or endothelial injury, immune responses, vascular supply, extracellular-matrix composition, mechanical forces, and disease duration vary by organ. A mechanism observed in one fibrotic model cannot automatically be transferred to another. Antifibrotic claims for MSCs or EVs therefore require product-specific and disease-specific evidence, including relevant functional outcomes and comparison with established care.
Figure 6 placeholder — Organ-specific fibrosis
Clinical takeaway
Fibrosis is not simply 'too much scar.' It is a dynamic failure of tissue repair involving fibroblasts, myofibroblasts, extracellular matrix, inflammatory signals, proteases, mechanics, and organ-specific biology.
Repair versus fibrosis
Normal repair requires temporary matrix production and wound contraction. Fibrosis develops when profibrotic signaling, matrix production, or failure of matrix resolution becomes persistent or excessive.
Transforming growth factor-beta signaling
TGF-beta is a major profibrotic pathway but acts within a larger network that includes mechanical tension, integrins, inflammatory mediators, oxidative stress, and cell-cell communication. Altering one pathway does not guarantee reversal of established fibrosis.
Matrix quantity versus quality
Matrix assessment should consider composition, organization, cross-linking, stiffness, and turnover—not merely total collagen. A smaller scar can still be mechanically poor or functionally harmful.
Timing and reversibility
Early inflammatory or fibroproliferative disease may respond differently from mature, heavily cross-linked fibrosis. Mechanisms that prevent fibrosis are not necessarily capable of reversing established scar.
Potency and biomarkers
Antifibrotic potency assays may measure fibroblast behavior, TGF-beta responses, collagen production, matrix degradation, or other relevant functions. Biomarkers can support mechanism but do not substitute for organ function or clinical outcomes.
Safety implications
Excessive inhibition of fibroblasts, collagen synthesis, or matrix remodeling could impair wound healing, tissue strength, vascular integrity, or normal repair. Antifibrotic activity therefore requires an appropriate therapeutic window.
Clinical interpretation
Changes in collagen staining, alpha-smooth-muscle actin, matrix metalloproteinases, or fibrosis biomarkers can support a mechanistic hypothesis but do not establish improved symptoms, organ function, or survival.
Knowledge gaps
Human mechanisms remain incompletely defined for many MSC and EV products, particularly in chronic established fibrosis where preclinical models may not reproduce disease duration, matrix maturity, comorbidities, or prior therapy.
Bottom-line evidence statement
Strong antifibrotic evidence distinguishes prevention from reversal, measures matrix quality as well as quantity, demonstrates organ-specific functional relevance, and keeps mechanistic findings separate from proof of clinical benefit.
Additional controlled terminology
A fibroblast can become a myofibroblast within the extracellular matrix during fibrosis. Transforming growth factor-beta and mechanical tension acting through an integrin can promote alpha-smooth-muscle actin expression. Collagen cross-linking, matrix turnover, tissue stiffness, and matrix organization influence scar quality. A matrix metalloproteinase is balanced by a tissue inhibitor of metalloproteinases, and excessive proteolysis can be harmful. Wound contraction and the fibroproliferative phase are normal repair processes that can become persistent through profibrotic signaling. An antifibrotic effect or fibrosis biomarker should be interpreted within a therapeutic window and linked to tensile strength or organ function. Fibrosis prevention and fibrosis reversal are distinct therapeutic claims.